Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma

Expert Review of Clinical Immunology
Nabila Bennani-BaitiStephen Ansell

Abstract

Hodgkin lymphoma's (HL) tumor composition is characterized by a paucity of malignant cells and a preponderance of immune and stromal cells. Despite the rich immune milieu within the tumor microenvironment, malignant cells are able to effectively evade the immune system and use immune support to promote lymphoma cell growth and proliferation. Recognizing this has led to the identification of checkpoint inhibitory signals that enable immune evasion and to opening the door to therapeutic strategies on how to exploit the immune system in targeting tumor cells. We discuss herein some of the tumor evasion mechanisms in HL with a particular focus on the immune checkpoint pathways and focus on recent clinical data of checkpoint blockade in HL treatment.

References

Nov 19, 1992·The New England Journal of Medicine·G P CanellosB A Peterson
Jan 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SantoroF Crippa
Aug 1, 1994·Immunity·T L WalunasJ A Bluestone
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FyfeA C Louie
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Mar 22, 2002·Nature Reviews. Immunology·M L AlegreC B Thompson
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raanan BergerArnon Nagler
Oct 11, 2008·Science·Kajsa WingShimon Sakaguchi
Oct 8, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen M AnsellJohn M Timmerman
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael R GreenMargaret A Shipp
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mizuki NishinoF Stephen Hodi
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Jul 1, 2014·Transplantation·Naoka Murakami, Leonardo V Riella
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 8, 2015·Current Opinion in Hematology·Stephen M Ansell
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok

❮ Previous
Next ❯

Citations

Nov 20, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B Bonavida, S Chouaib
Apr 24, 2021·Frontiers in Immunology·Shanqiang QuHuafu Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

© 2021 Meta ULC. All rights reserved